Brokerages Expect PDL BioPharma Inc (PDLI) Will Post Earnings of $0.03 Per Share

Wall Street brokerages expect PDL BioPharma Inc (NASDAQ:PDLI) to report earnings per share (EPS) of $0.03 for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for PDL BioPharma’s earnings. PDL BioPharma posted earnings of $0.01 per share in the same quarter last year, which suggests a positive year over year growth rate of 200%. The business is scheduled to issue its next quarterly earnings report after the market closes on Thursday, March 8th.

On average, analysts expect that PDL BioPharma will report full-year earnings of $0.60 per share for the current fiscal year. For the next financial year, analysts forecast that the firm will post earnings of $0.10 per share. Zacks’ earnings per share calculations are an average based on a survey of research firms that follow PDL BioPharma.

PDLI has been the topic of several research reports. ValuEngine raised PDL BioPharma from a “hold” rating to a “buy” rating in a research report on Saturday, November 25th. BidaskClub lowered PDL BioPharma from a “hold” rating to a “sell” rating in a research report on Saturday, January 6th. Zacks Investment Research lowered PDL BioPharma from a “buy” rating to a “hold” rating in a research report on Monday, January 8th. Finally, Cowen reaffirmed a “hold” rating and issued a $3.00 target price on shares of PDL BioPharma in a research report on Friday, October 27th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $3.33.

Large investors have recently added to or reduced their stakes in the business. Dynamic Technology Lab Private Ltd purchased a new position in PDL BioPharma in the third quarter valued at about $131,000. Cubist Systematic Strategies LLC raised its position in PDL BioPharma by 64.0% in the third quarter. Cubist Systematic Strategies LLC now owns 49,062 shares of the biotechnology company’s stock valued at $166,000 after purchasing an additional 19,144 shares during the period. Spark Investment Management LLC purchased a new position in PDL BioPharma in the fourth quarter valued at about $142,000. Jane Street Group LLC purchased a new position in PDL BioPharma in the fourth quarter valued at about $142,000. Finally, Teacher Retirement System of Texas raised its position in PDL BioPharma by 312.9% in the fourth quarter. Teacher Retirement System of Texas now owns 52,122 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 39,499 shares during the period. 89.42% of the stock is currently owned by institutional investors.

PDL BioPharma (NASDAQ:PDLI) opened at $2.48 on Thursday. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.16 and a quick ratio of 3.10. The firm has a market capitalization of $375.04, a price-to-earnings ratio of 4.86 and a beta of 0.48. PDL BioPharma has a 52-week low of $1.96 and a 52-week high of $3.55.

TRADEMARK VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2018/02/15/brokerages-expect-pdl-biopharma-inc-pdli-will-post-earnings-of-0-03-per-share.html.

About PDL BioPharma

PDL BioPharma, Inc seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company’s segments include income generating assets and product sales.

Get a free copy of the Zacks research report on PDL BioPharma (PDLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for PDL BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply